- Iovance Biotherapeutics focuses on developing treatments for cancers, a market with minimal supply and large demand.
- The company recently received approval to proceed with further investigations into a revolutionary new treatment for NSCLCs.
- The company relies on smart partnerships for research and development to avoid accruing excess debt.
- Iovance has no viable products on the market to date, which means they generate no revenue or profit, which adds significant risk to investment.
For further details see:
Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside